title: Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
abstract: Moderate doses of methotrexate and L-asparaginase were added to standard doses fo 5-fluorouracil, Adriamycin, and cyclophosphamide in an attempt to improve the overall response rate and survival following chemotherapy. In addition, nonspecific immunotherapy with either Corynebacterium parvum or Pseudomonas vaccine was integrated into this prospective randomized clinical trial. The overall toxicity (degree of granulocytopenia and thrombocytopenia, length of myelosuppression, and incidence of myelosuppression-related infection and infectious deaths) increased considerably and led to the termination of patient accrual. The incidence of stomatitis and diarrhea was also increased with the addition of methotrexate and L-asparaginase, and apparently was potentiated by the addition of Pseudomonas vaccine to this five-drug combination.
mesh_terms: D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001215:Asparaginase / Q000008:administration & dosage; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D001772:Blood Cell Count / Q000187:drug effects; D001943:Breast Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D008727:Methotrexate / Q000008:administration & dosage; D009325:Nausea / Q000139:chemically induced; D011425:Propionibacterium acnes / Q000276:immunology; D011549:Pseudomonas / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D001428:Bacterial Vaccines; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D005472:Fluorouracil; D008727:Methotrexate